Barclays Initiates Coverage on Alcobra Ltd(NASDAQ:ADHD). The shares have been rated Equal-weight. The rating by Barclays was issued on Aug 1, 2016.
In a different note, On Jun 21, 2016, Roth Capital said it Reinstates its rating on Alcobra Ltd. The shares have been rated ‘Buy’ by the firm. Cantor Fitzgerald said it Initiates Coverage on Alcobra Ltd, according to a research note issued on Jun 7, 2016. The shares have been rated ‘Buy’ by the firm.
Alcobra Ltd (ADHD) shares turned negative on Mondays trading session with the shares closing down -0.09 points or -1.86% at a volume of 1,02,442. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $4.84. The peak price level was also seen at $4.84 while the days lowest was $4.7. Finally the shares closed at $4.75. The 52-week high of the shares is $9.5 while the 52-week low is $3.15. According to the latest information available, the market cap of the company is $131 M.
Alcobra Ltd(ADHD) last announced its earnings results on May 16, 2016 for Fiscal Year 2016 and Q1.Earnings per share were $-0.18. Analysts had estimated an EPS of $-0.22.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug MG01CI to treat Attention Deficit Hyperactivity Disorder (ADHD) a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs higher divorce rates lower levels of socioeconomic attainment lower academic achievement unemployment and work place deficits increased risks for motor vehicle accidents greater likelihood of additional psychiatric disorders increased criminal activity and incarceration and higher rates of substance use and abuse. MG01CI product has completed phase two studies.